Last update 11 Oct 2025

IMD-101

Overview

Basic Info

Drug Type
Biological products
Synonyms
IMD 101, IMD101
Target
IL-2
Action
inhibitors
Mechanism
IL-2 inhibitors(Interleukin-2 inhibitors)
Therapeutic Areas
NeoplasmsRespiratory DiseasesSkin and Musculoskeletal Diseases+ [1]
Active Indication
Advanced Malignant Solid NeoplasmBladder CancerKidney Neoplasms+ [4]
Inactive Indication-
Originator Organization
Shanghai Affinity Biopharmaceutical Co., Ltd.Shanghai Affinity Biopharmaceutical Co., Ltd.
Active Organization
Catalysis Therapeutics Pty LtdShanghai Affinity Biopharmaceutical Co., Ltd.Shanghai Affinity Biopharmaceutical Co., Ltd.Shanghai Yingmaide Medical Technology Co., Ltd.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with IMD-101
CTR20253162
/ Not yet recruitingPhase 1
评价IMD101注射液治疗晚期恶性实体瘤患者的安全性、耐受性、药代动力学特征以及初步疗效的开放、剂量递增的国际多中心I期临床试验
[Translation] An open-label, dose-escalating, international, multicenter Phase I clinical trial evaluating the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of IMD101 injection in patients with advanced malignant solid tumors
100 Clinical Results associated with IMD-101
Login to view more data
100 Translational Medicine associated with IMD-101
Login to view more data
100 Patents (Medical) associated with IMD-101
Login to view more data
100 Deals associated with IMD-101
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Malignant Solid NeoplasmPhase 1
China
Shanghai Yingmaide Medical Technology Co., Ltd.
18 Aug 2025
Kidney NeoplasmsPhase 1
Australia
Catalysis Therapeutics Pty Ltd
15 Jan 2024
MelanomaPhase 1
Australia
Catalysis Therapeutics Pty Ltd
15 Jan 2024
MesotheliomaPhase 1
Australia
Catalysis Therapeutics Pty Ltd
15 Jan 2024
Non-Small Cell Lung CancerPhase 1
Australia
Catalysis Therapeutics Pty Ltd
15 Jan 2024
Bladder CancerPhase 1
Australia
Catalysis Therapeutics Pty Ltd
15 Jan 2024
Solid tumorPhase 1
Australia
Shanghai Affinity Biopharmaceutical Co., Ltd.Shanghai Affinity Biopharmaceutical Co., Ltd.
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free